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The aim was to investigate the genetic background of familial clustering of type 2 diabetes. 26 
Subjects and Methods 27 
We recruited Japanese families with a 3-generation history of diabetes. Genome-wide linkage 28 
analysis was performed assuming an autosomal dominant model. Genes in the linkage region 29 
were computationally prioritized using Endeavour. We sequenced the candidate genes, and 30 
the frequencies of detected nucleotide changes were then examined in normoglycemic 31 
controls. 32 
Results 33 
To exclude known genetic factors, we sequenced 6 maturity onset diabetes of the young 34 
(MODY) genes in 10 familial cases. Because we detected a MODY3 mutation HNF1A 35 
R583G in one case, we excluded this case from further investigation. Linkage analysis 36 
revealed a significant linkage region on 2p25-22 (LOD score = 3.47) for 4 families. The 37 
23.6-Mb linkage region contained 106 genes. Those genes were scored by computational 38 
prioritization. Eleven genes, i.e., top 10% of 106 genes, were selected and considered them as 39 
primary candidates. Considering their functions, we eliminated 3 well characterized genes 40 
and finally sequenced 8 genes. GCKR ranked highly in the computational prioritization. 41 
Mutations (minor allele frequency less than 1%) in exons and the promoter of GCKR were 42 
found in index cases of the families (3 of 18 alleles) more frequently than in controls (0 of 36 43 
alleles, P=0.033). In one pedigree with 9 affected members, the mutation GCKR g.6859C>G 44 
was concordant with affection status. No mutation in other 7 genes that ranked highly in the 45 




We propose that GCKR is a susceptibility gene in Japanese families with clustered diabetes. 48 
The family based approach seems to be complementary with a large population study. 49 
 50 
Keywords: Genetic susceptibility, Linkage analysis, MODY, HNF1A, GCKR 51 
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Abbreviations: 53 
GAD: Glutamic acid decarboxylase 54 
GCKR: Glucokinase regulator 55 
HLOD: Heterogeneity logarithm of the odds 56 
HNF4α: Hepatocyte Nuclear Factor 4α 57 
LOD: Logarithm of the odds 58 
MAF: Minor allele frequency 59 
MODY: Maturity onset diabetes of the young 60 
RFLP: Restriction fragment length polymorphism 61 




1. Introduction 64 
 65 
The national survey in 2007 reported that 8.9 million people suffer from diabetes in Japan [1]. 66 
Most of these have type 2 diabetes, and the number of such patients has increased 67 
continuously. Both genetic and environmental factors play important roles in the pathogenesis 68 
of type 2 diabetes [2]. 69 
  To elucidate the genetic factors underlying the pathogenesis of type 2 diabetes in the 70 
Japanese population, several genome-wide linkage analyses in Japanese sib-pairs have been 71 
performed [3-5]. Linkage to 11p13–p12 is consistently implicated in these studies [5]. Recent 72 
successes with genome-wide association analyses in the Japanese population have revealed a 73 
susceptibility variant in KCNQ1 located at 11p15.5 [6, 7], a locus not far from the region 74 
suggested in linkage analyses. The association of susceptibility loci including TCF7L2, 75 
CDKAL1, CDKN2A/B, IGF2BP2, SLC30A8, and HHEX with diabetes has been established in 76 
Caucasian populations and replicated in the Japanese population [8]. However, the loci 77 
identified in association studies have uniformly small effect sizes, and can explain only a 78 
small portion of the genetic background of diabetes in the Japanese population. Approaches 79 
other than sib-pair linkage analyses and association analyses may therefore be required to 80 
elucidate a greater aspect of the genetic background of type 2 diabetes. 81 
  In the present study, we used a family-based approach, because high degrees of familial 82 
clustering can raise the relative risk and provide better insight to novel loci of larger effect 83 
size [9]. Familial clustering of diabetes is well known, the typical example being MODY [10]. 84 
On the other hand, in most families in Japan, familial clustering cannot be attributed to 85 
mutations of the 6 known MODY genes [10], and genetic predisposition in such families has 86 
not been ascertained. 87 
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  We recruited families having a 3-generation history of diabetes and performed 88 
genome-wide linkage analysis. We selected candidate genes in the linked chromosomal 89 
region and searched for rare and common nucleotide changes the genes in familial cases and 90 




2. Material and Methods 93 
 94 
2.1. Families and Additional Index Cases 95 
 96 
We recruited patients from collaborating hospitals in Japan who had diabetes with a 97 
3-generation family history, which is suggestive of autosomal dominant mode of inheritance 98 
[11]. If ≥2 family members with diabetes were alive and donated DNA, the families were 99 
regarded as suitable subjects for the present study. Families including members with positive 100 
GAD (Glutamic Acid Decarboxylase) antibody were excluded from the study. Four families 101 
met these criteria and were included in the linkage analysis (Figure 1). Affected status of the 102 
participants was determined in two ways. First, if participants had been diagnosed with 103 
diabetes and treated with oral hypoglycemic agents or insulin injection, they were regarded as 104 
affected. Second, if participants had not been treated with oral hypoglycemic agents or insulin 105 
injection, they underwent HbA1c (Hemoglobin A1c) measurement for screening of impaired 106 
glucose tolerance. The value for HbA1c is estimated as an NGSP (US National 107 
Glycohemoglobin Standardization Program) equivalent value (%) calculated by the formula 108 
HbA1c (%) = HbA1c (JDS, Japanese Diabetes Society) (%) + 0.4%, considering the 109 
relational expression of HbA1c (JDS)(%) measured by the previous Japanese standard 110 
substance and measurement methods and HbA1c (NGSP) [12]. If their HbA1c levels were 111 
≥6.0%, they were also regarded as affected. HbA1c ≥6.0% is the level defined as possible 112 
diabetes mellitus in the 2007 survey of the Ministry of Labor, Health and Welfare of Japan [1]. 113 
In addition to these subjects, 6 index cases from other families with a 3-generation history of 114 
diabetes were included in the study (Supplementary Figure 1). In these families, although we 115 
confirmed the affected status of some of the family members, DNA samples were available 116 
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only for the index cases but not for other family members. Together with the 4 index cases 117 
from the families included in the linkage analysis, a total of 10 unrelated cases with a 118 
3-generation history of diabetes were available for DNA sequencing. The clinical features of 119 
family members and additional index cases are shown in Table 1. 120 
 121 
2.2. Normoglycemic controls 122 
 123 
An annual medical check-up program was performed in Nyukawa district of Takayama 124 
City, Japan. Nine-hundred ninety local residents (430 men, 560 women) were recruited in the 125 
program and consented to donate their DNA. From 2002 to 2007, participants underwent 126 
physical examination and blood tests including fasting plasma glucose and HbA1c every year. 127 
We selected normoglycemic controls from the participants in the cohort. Subjects defined as 128 
normoglycemic controls had the following characteristics: HbA1c <6.0% and fasting plasma 129 
glucose <5.5mmol/l during 5-year follow-up span, and age ≥55. The number of subjects that 130 
satisfied the definition was 206 (81 men, 125 women).  131 
 132 
2.3. Genotyping Family Members 133 
 134 
Genomic DNA was extracted from blood samples with a QIAamp DNA Blood Mini Kit 135 
(Qiagen Inc). PCR amplification from genomic DNA was performed with 136 
fluorescence-labeled (6-FAM, HEX, NED) and tailed primers. PCR primers to analyze 137 
microsatellite markers comprised an approximately 10cM human index map (ABI Prism 138 
Linkage Mapping Set Version 2.5: 382 markers for 22 autosomes), and other microsatellite 139 
fine markers were designed according to information from the UniSTS map. PCR reactions 140 
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were carried out in 7.5 μl with 50 ng genomic DNA, using AmpliTaq Gold DNA Polymerase 141 
(Applied Biosystems) in a 2-step amplification program. DNA fragments were analyzed on 142 
an Applied Biosystems 3130 Genetic Analyzer. Genotyping errors and inconsistent 143 
relationships were checked with the use of GENEHUNTER (version 2.1) software [13]. If the 144 
results of genotyping were missed or ambiguous, we treated them as an unknown genotype in 145 
the linkage analysis. The rate of genotyping failure was 0.057% (7/11842). 146 
 147 
2.4. Linkage and Haplotype Analyses 148 
 149 
Both affected and unaffected family members were included in the linkage analysis. 150 
Participants with HbA1c level <6.0% were considered as unaffected if the age was ≥55 and 151 
as unknown if the age was <55, considering the assumed age-dependent penetrance of 152 
diabetes. The purpose of including members assigned as unknown was to increase the 153 
accuracy of haplotype estimation in affected members, although inclusion did not increase the 154 
statistical power. Multipoint parametric analyses for autosomes were run using 155 
GENEHUNTER assuming an autosomal dominant model [13]. Because locus heterogeneity 156 
could be associated with diabetes, LOD (log of the odds) score and HLOD (heterogeneity 157 
LOD) score were calculated. The disease allele frequency was set at 0.00001 and a 158 
phenocopy frequency of 0.00001 was assumed. Population allele frequencies for each 159 
microsatellite marker were assigned equal portions for individual alleles. We used a 2-stage 160 
design: first, all chromosomal regions were screened by genotyping at an approximately 161 
10cM density (screening), and the regions where LOD scores were highest were considered 162 
potentially interesting. Second, these regions were further finely mapped at approximately 1- 163 
to 2-cM densities (fine mapping). Regions where LOD scores were above 3.3, a level 164 
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corresponding to genome-wide significance [9], were considered as linkage regions. 165 
Haplotypes were constructed with the GENEHUNTER program. 166 
 167 
2.5. Prioritization of Candidate Genes 168 
 169 
The 23.6-Mb linkage region on chromosome 2p25-22 contained 106 genes annotated in 170 
Ensemble genome browser (www.ensembl.org). The genes were computationally prioritized 171 
using Endeavour (www.esat.kuleuven.be/endeavour/) [14]. We selected 6 MODY genes 172 
(HNF4A, GCK, HNF1A, PDX1, HNF1B, and NEUROD1) as training genes because a 173 
dominant mode of inheritance was assumed in the highly clustered families in linkage 174 
analysis. We adopted all databases available in Endeavour, which prioritized glucokinase 175 
regulator (GCKR) at the first rank. 176 
 177 
2.6. Sequencing 178 
 179 
We directly sequenced the coding exons of 6 MODY genes (HNF4A, GCK, HNF1A, PDX1, 180 
HNF1B, and NEUROD1) in the 10 index cases. We sequenced GCKR including all exons 181 
found in the National Center for Biotechnology Information (NCBI) Evidence Viewer 182 
(www.ncbi.nlm.nih.gov) and the 2-kb promoter region in the index cases from families and in 183 
control subjects. We also selected other 7 genes that are highly prioritized within the 11th 184 
rank (10.3%) in the linkage region using Endeavour excluding 3 genes with known metabolic 185 
functions unrelated to glucose metabolism (Supplementary Table 1). We sequenced the entire 186 
coding exons of the 7 genes in the index cases from families included in the linkage analysis. 187 
Forward and reverse PCR primers for each exon were selected in an intronic sequence 50 bp 188 
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away from the intron/exon boundaries and primers to amplify the GCKR promoter region 189 
were also selected. Sequencing primer data for GCKR is shown in Supplementary Table 2. 190 
PCR products were run on 2% agarose gel, and the appropriate bands were excised and then 191 
purified with the use of the QIAquick Gel Extraction Kit (Qiagen). Sequencing results were 192 
analyzed on an ABI Prism 3130 Avant DNA sequencer (Applied Biosystems). Any nucleotide 193 
changes identified in sequencing were searched for SNPs (single nucleotide polymorphisms) 194 
in the dbSNP database (www.ncbi.nlm.nih.gov/SNP/). 195 
 196 
2.7. Genotyping SNPs 197 
 198 
If minor allele frequencies (MAF) of nucleotide changes identified in sequencing were 199 
unregistered in the HapMap JPT database on dbSNP as of April 2010 and the minor allele 200 
appeared in <2 of all subjects, MAF was determined in the expanded population. We defined 201 
mutation as MAF<1% [15]. To determine whether each nucleotide change was a mutation or 202 
not, we genotyped 105 normoglycemic controls randomly selected from the cohort 203 
(Supplementary Table 3), because genotyping of 210 normal chromosomes is necessary to 204 
achieve 80% power to detect a polymorphism present in 1% of the population [16]. The 205 
PCR-RFLP (restriction fragment length polymorphism) method for HNF1A R583G, GCKR 206 
g.-689G>A, GCKR g.-299G>A, GCKR E252K and FOSL2 R198H and Taqman method for 207 
GCKR g.6859C>G were used. 208 
 209 
2.8. Statistical analysis 210 
 211 
Frequencies of mutations (MAF<1%) and common nucleotide changes (MAF≥1%) 212 
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identified in GCKR sequencing in the index cases and in normoglycemic controls were 213 
compared by the Fisher exact test with SAS software (version 8.2). 214 
 215 
2.9. Ethics 216 
 217 
The methods used in this study were approved by the Ethics Committee of the Kyoto 218 
University Institutional Review Board, and approved written informed consent was obtained 219 




3. Results 222 
 223 
3.1. Characteristics of Family Members 224 
 225 
Four families with a 3-generation history of diabetes were enrolled in this study (Figure 1, 226 
Table 1). Every family included no less than 1 member that had been diagnosed with diabetes 227 
before the age of 50. Sixteen members (6 men, 10 women) had previously been diagnosed 228 
with diabetes. Thirteen out of the 16 members with diabetes were lean (BMI<25). Six 229 
members were treated with insulin and another 10 members were treated with oral 230 
hypoglycemic agents. Twelve family members who had not been diagnosed with diabetes 231 
underwent HbA1c measurement and 3 of them had HbA1c level ≥ 6.0%. These 3 members 232 
had already been diagnosed with impaired glucose tolerance before this study and were 233 
included as affected members in the study.  234 
 235 
3.2. Exclusion of MODY gene mutations in the index cases 236 
 237 
For the 10 index cases, we performed direct sequencing in entire coding exons of the MODY 238 
genes. The detected missense SNPs were HNF1A I27L (rs1169288), HNF1A S487N 239 
(rs2464196), HNF1A R583G, and HNF4A T117I (rs1800961) (Supplementary Table 4). 240 
HNF1A R583G is a mutation that is reported to cause MODY [17], thus we excluded the 241 
carrier of the mutation (additional index case #6, Table 1) from further investigation. HNF1A 242 
I27L and HNF1A S487N are common in the general population (MAF=0.386 and 0.341, 243 
respectively in HapMap-JPT). HNF4A T117I was associated with late-onset type 2 diabetes 244 




3.3. Linkage Analysis 247 
 248 
A total of 30 members (19 affected members) from 4 families were included in the linkage 249 
analysis, assuming an autosomal dominant model. The genome-wide linkage results in the 250 
screening are shown in Figure 2. Regions of potential interest by multipoint LOD and HLOD 251 
scores were observed on chromosomes 2p24 and 7q34. After fine mapping, 2p25-22 was 252 
revealed to be a significant linkage region (Figure 3, LOD and HLOD=3.47) while the region 253 
on 7q34 was discarded. The size of the region with positive HLOD score was 23.6Mb 254 
(D2S2199-D2S2230). In the region, a haplotype segregated in affected and unaffected 255 
members in the pedigrees 1, 2, and 3, but not in the pedigree 4. 256 
 257 
3.4. Candidate Genes 258 
 259 
We searched candidate genes in the implicated linkage region by applying a gene 260 
prioritization approach implemented in Endeavour software. We selected 6 MODY genes as 261 
training genes. The 2 top-ranked genes were glucokinase regulatory protein (GCKR) and 262 
nuclear receptor coactivator 1 (NCOA1). GCKR ranked high in prioritization using gene-gene 263 
interaction databases (first rank in 5 out of 7 interaction databases), mainly because the 264 
interaction of glucokinase and glucokinase regulatory protein has been demonstrated in 265 
previous studies [19, 20]. NCOA1 also ranked high in prioritization using gene-gene 266 
interaction databases (second rank in 2 out of 7 interaction databases), because nuclear 267 
receptor coactivator 1 has been reported to interact with HNF4α (Hepatocyte Nuclear Factor 268 
4α) as a coactivator [21]. Together with GCKR and NCOA1, genes that are highly prioritized 269 
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within the 11th rank (10.3% of annotated genes) were considered as candidate genes except 3 270 
genes with well-characterized metabolic functions unrelated to glucose metabolism 271 
(Supplementary Table 1). 272 
 273 
3.5. Direct Sequencing in GCKR and other candidate genes 274 
 275 
We performed direct sequencing in exons and the 2-kb promoter region of GCKR. 276 
Sequencing was performed in 9 index cases from families and in 18 normoglycemic controls 277 
in parallel. The 18 control subjects were randomly selected from 206 normoglycemic controls 278 
(Supplementary Table 3). Detected sequence changes in the 9 index cases and 18 controls are 279 
shown in Table 2. Five nucleotide changes (g.-959 Insertion AATGTTG, E66E, E77G, 280 
g.9709G>A, and L446P) were considered to be common variants, because the minor allele 281 
was found in not less than 2 subjects out of a total of 27 case and control subjects. To 282 
determine whether or not each of the other nucleotide changes (g.-689G>A, g.-299G>A, 283 
E252K and g.6859C>G) was a mutation (MAF<1%), genotyping was performed in a total of 284 
105 normoglycemic controls. g.-689G>A, g.-299G>A and g.6859C>G were not detected in 285 
the 105 controls, and were regarded as mutations, while E252K was detected in 4 controls out 286 
of 105 (MAF=1.9%) and was regarded as a common change. The number of alleles having 287 
mutations was thus significantly larger in the index cases from families than in the controls 288 
(3/18 alleles vs. 0/36 alleles, P=0.033, Fisher exact test). 289 
  We performed direct sequencing in the entire coding exons of other 7 candidate genes in 290 
index cases from 4 families. One misssense mutation FOSL2 R198H (MAF=0.004 in 291 
normoglycemic controls) was detected. No other mutations were detected in other 6 genes 292 




3.6. Segregation of the mutations with the Phenotype in Pedigrees 295 
 296 
In index cases from the 4 families included in the linkage analysis, 3 sequence changes of 297 
GCKR were detected (g.-959 Insertion AATGTTG, g.6859C>G and L446P). We tested the 298 
segregation of GCKR g.6859C>G, a mutation detected in pedigree 3, with the phenotype in 299 
the pedigree. Another 2 changes (GCKR g.-959 Insertion AATGTG and GCKR L446P) were 300 
commonly detected in controls (3/36 alleles and 11/36 alleles respectively). In pedigree 3, 301 
GCKR g.6859C>G was detected in all 9 affected members, but was not detected in the 302 
unaffected member (II-7). We performed linkage analysis and haplotype construction in 303 
2p25-22 using the GCKR g.6859 genotype together with the microsatellite markers. The 304 
parametric multipoint LOD score for pedigree 3 was 2.67 at the GCKR g.6859 locus. 305 
Haplotype analysis revealed that all affected individuals in pedigree 3 shared a disease 306 
haplotype within D2S2199-D2S2230, which includes GCKR g.6859G (Figure 4). In pedigree 307 
3, another sequence change, GCKR L446P, was detected, but GCKR L446P did not 308 
co-segregate with the disease. Haplotype analysis revealed that the minor allele of GCKR 309 
L446P (g.11169C) resided on a different haplotype than GCKR g.6859G in affected subjects 310 
III-11, 12, 13, 14 (Figure 4). 311 
We tested the segregation of FOSL2 R198H, a mutation detected in pedigree 4, with the 312 
phenotype. FOSL2 R198H was detected in 2 affected subjects (II-2, II-22) but not detected in 313 




4. Discussion and Conclusions 316 
 317 
Recent progress in genome-wide association studies has identified tens of type 2 diabetes 318 
susceptibility genes. Even so, only a small portion of the genetic background of diabetes has 319 
been explained in the Japanese population. The loci identified in association studies have 320 
only very small effect sizes. We hypothesized that rare disease variants with larger effect 321 
sizes remain to be discovered that may explain a greater part of the genetic background. 322 
Family-based linkage study is an important alternative for the identification of rare disease 323 
variants. Indeed, studies with large families with highly clustered diabetes have revealed 324 
important mutations involved in MODY and other dominantly inherited diabetes, including a 325 
KCNJ11 mutation [22]. We therefore recruited families with a 3-generation history of 326 
diabetes. The validity of our strategy was strengthened by the fact that one case out of the 10 327 
index cases recruited in our study carried a previously reported rare disease variant HNF1A 328 
R583G. 329 
Our family analysis revealed a significant linkage region on chromosome 2p25-22 that has 330 
not been reported in previous Japanese sib-pair analyses [3-5]. Because our approach was 331 
based on a higher degree of familial clustering than sib-pair analyses, the linkage region 332 
suggested in the present study might well go undetected in sib-pair analyses that include an 333 
admixture of sib-pairs with both low and high degrees of familial clustering. In the present 334 
study, we conducted a computational approach targeting the linkage region on chromosome 335 
2p25-22. One hundred and six known genes were present in this linkage region. Prioritization 336 
of the candidate gene was possible by integrating the information available from multiple 337 
publicly available databases [14]. GCKR and other 7 gens ranked high in the prioritization, 338 
and were selected as candidate genes.  339 
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GCKR regulates glucokinase (GCK), the first glycolytic enzyme, in liver. GCKR-null mice 340 
exhibit elevated postprandial glucose [19]. Adenoviral-mediated overexpression of GCKR in 341 
mouse liver increases GCK activity and lowers fasting blood glucose. It was suggested that 342 
GCKR, a competitive inhibitor of GCK activity, also has a paradoxical role in extending 343 
GCK half-life by stabilizing the enzyme [20]. If so, diminished expression of GCKR in 344 
human might cause decreased GCK activity in liver and lead to impaired liver glucose uptake, 345 
which suggests the GCKR mutation as a possible cause of the disease in linked families.  346 
We sequenced entire exons and the 2-kb promoter region of GCKR in 9 index 3-generation 347 
cases and in 18 control subjects. The rare variants were significantly more frequent in index 348 
cases from families than in control subjects. In addition, exonic rare variant g.6859C>G in 349 
pedigree 3, which was not detected in 105 control subjects, was clearly segregated in all 9 350 
affected members in pedigree 3. Previous reports have shown the association of common 351 
GCKR variants with fasting plasma glucose, glucose level after glucose challenge, and 352 
diabetes risk in various ethnic groups [23-30]. In Japanese population, a common variant 353 
GCKR rs780094 is associated with fasting glucose and diabetes risk [27, 30]. Our family 354 
study suggests the effect of rare GCKR variants on diabetes susceptibility that has not been 355 
revealed by previous association studies. A recent study has shown the excess of rare GCKR 356 
variants in individuals with hypertriglyceridemia [31], which supports our idea that rare 357 
GCKR mutations also affect the diabetes susceptibility. 358 
On the other hand, the only one mutation in other 7 highly prioritized genes was FOSL2 359 
R198H and it did not co-segregate with the phenotype in the pedigree. Therefore, we 360 
tentatively eliminate the possibility that these genes are involved in familial clustering of 361 
diabetes patients in the current pedigrees.  362 
Our study has several limitations. First is the large size (23.6Mb) of the linkage region. 363 
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Only 4 families could be included in the linkage analysis because we limited the cohort to 364 
3-generation families with ≥2 affected members who donated DNA. Further efforts to recruit 365 
large families are needed to narrow down the linkage region. Second, because the GCKR 366 
g.6859C>G mutation was in a non-coding exon, confirming the relevance of the mutation as 367 
the cause of the disease is difficult. Investigation of the effect of the mutation in human liver, 368 
where GCKR is predominantly expressed [32], is required, but liver specimens of family 369 
members are currently unavailable. Although we tried to determine the mRNA level in 370 
peripheral blood of family members, GCKR mRNA was only barely detectable with the 371 
RT-PCR method (data not shown), so comparison of the GCKR mRNA level between 372 
affected and unaffected members was not possible. We speculate that the g.6859C>G mutatin 373 
might affect GCKR function in liver through mRNA transcription or splicing processes [33]. 374 
GCKR g.-689G>A and g.-299G>A mutations located in the promoter also might affect the 375 
expression of GCKR, but TRANSFAC database [34] expected no binding sites of 376 
transcription factors at the two promoter mutations.  377 
In conclusion, with systematic investigation we propose that GCKR is a susceptibility gene 378 
in Japanese families with clustered diabetes. A family-based approach may be a promising 379 
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Table 1. Characteristics of family members and additional index cases. 591 
 





Pedigree 1 II-4 70 F 16.2  5.0      
 
II-5 71 F 22.5  10.6  60 (DM) Insulin 66U/d 
 
III-1 40 F 21.9  5.4  
  
 
III-2 37 M 26.0  6.9  20 (DM) Insulin 
Pedigree 2 II-1 79 M 19.2  7.5  50 (DM) Insulin 25U/d 
 
II-2 77 F 18.6  5.6  
  
 
II-3 76 M 17.9  7.2  45 (DM) Insulin 
 
II-5 74 M 18.2  6.0  64 (IGT) Diet 
 
II-6 71 F 18.4  6.6  N/A (DM) Oral drug 
 
II-7 68 F 19.9  5.9  
  
 
III-1 53 M 24.2  6.0  53 (IGT) Diet 
 
III-3 51 M 20.4  5.6  
  
 
III-4 47 F 19.3  5.2  
  
 
III-5 46 F 19.6  4.9  
  
 
IV-1 23 M 19.9  5.6  
  
Pedigree 3 II-7 92 F 22.3  5.9      
 
III-2 77 F 23.9  9.3  30 (DM) Oral drug 
 
III-5 72 F 22.0  8.1  60 (DM) Insulin 16U/d 
 
III-6 69 F 19.8  8.0  65 (DM) Insulin 16U/d 
 
III-8 66 F 19.1  6.5  64 (IGT) Diet 
 
III-10 59 F 19.3  10.2  57 (DM) Oral drug 
 
III-11 67 F 20.4  6.9  62 (DM) Oral drug 
 
III-12 66 M 21.1  N/A 57 (DM) Oral drug 
 
III-13 64 F 20.0  6.6  25 (DM) Insulin 
 
III-14 62 M 20.2  10.3  50 (DM) Oral drug 
Pedigree 4 II-1 76 F 28.2  6.7  60 (DM) Oral drug 
 
II-2 73 F 25.1  6.4  50 (DM) Oral drug 
 
II-3 67 F 19.0  5.5  
  
 
II-4 64 M N/A 5.4  
  
 
III-1 52 F 20.4  5.3  
  
  III-2 50 M 20.8  6.2  35 (DM) Oral drug 
Additional Index 
Cases 
1 57 M 25.7  7.1  30 (DM) Oral drug 
2 47 F 22.9  10.0  36 (DM) Insulin 20U/d 
3 68 F 19.7  7.1  45 (DM) Insulin 19U/d 
4 60 F 24.7  10.4  40 (DM) Insulin 51U/d 
 
5 60 F 28.0  9.7  50 (DM) Insulin 8U/d 
  6 54 F 34.5  9.1  40 (DM) Insulin 
    
 




Table 2. Mutations and common nucleotide changes in exons and the promoter of GCKR in 9 index cases in families and in 18 controls. 592 
 593 
       Detected Number of Alleles      
 
   
Index Cases from 
Families (n=9) 
  Controls(n=18)    




Mutations (MAF<1%)             
Promoter g. -689G>A   17 1  36 0 0.33  0.000 b 
Promoter g. -299G>A   17 1  36 0 0.33  0.000 b 
Exon 9 g. 6859C>G Noncoding exon  17 1  36 0 0.33  0.000 b 
            
Total      15 3   36 0 0.033    




  16 2  33 3 1.00   N/D 
Exon 2 g. 468G>A Synonymous E66E 17 1  35 1 1.00   N/D 
Exon 3 g. 671A>G Missense E77G 17 1  33 3 1.00   0.024 c 
Exon 10 g. 8817G>A Missense E252K 18 0  35 1 1.00   0.019 b 
Exon 11 g. 9709G>A Noncoding exon  17 1  33 3 1.00   0.123 c 
Exon 14 g. 11169T>C Missense L446P 8 10  25 11 0.087   0.467 c 
GenBank Accession No. NT_022184.15 594 




Figure Captions 597 
 598 
Figure 1. Four pedigrees with familial aggregated diabetes mellitus. 599 
 600 
Figure 2. Multipoint HLOD and LOD scores in genome-wide linkage analysis for 4 pedigrees. 601 
 602 
Figure 3. Multipoint HLOD and LOD scores in fine mapping of D2S168-D2S2259 and D7S640-D7S636. 603 
 604 










Symbol Description Known metabolic function 
1 GCKR Glucokinase regulatory protein  
2 NCOA1 Nuclear receptor coactivator 1  
3 FOSL2 Fos-related antigen 2  
4 APOB Apolipoprotein B-100 precursor Lipid Metabolism 
a
 
5 MYCN N-myc proto-oncogene protein  
6 RBKS Ribokinase  
7 XDH Xanthine dehydrogenase/oxidase Purine Metabolism 
a
 
8 KHK Ketohexokinase  
9 NRBP1 Nuclear receptor-binding protein  
10 CAD Glutamine-dependent carbamoyl-phosphate synthase, 




11 RDH14 Retinol dehydrogenase  
a 
Excluded from candidate genes
 
Supplementary Table 2. Sequencing Primers for GCKR 
    
GCKR    
 Forward  Reverse 
promoter1a TGACTAGCTGTGGTTGACCCT promoter1b ATCTCCCTCACTCTCTCCCCT 
promoter2a CCCCATCCCTTATCCCTTCT promoter2b TGGACAAATTGGGACTCACA 
promoter3a GGGTTGTTGTGAGGCTCAAAT promoter3b TCCGGGGTCTCAATGACAT 
1a TAGTGACCAGGAAAGGGTGGT 1b CCAAAAGGGAGAAAGGAGAA 
1c TAATATGCCCAGAGCACCAA   
2a AGCAAGACATGGGAGTCAAA 2b TGAGGGAATAAGGAATGGTGA 
3a AATGTAGCCTGCCCTAATACG 3b CCTTCTAGCACCGATCTCATT 
4a TTCTGATGCACTTGAGCCTT 4b TTATAAGCTTAGGGGCACCC 
5a ACCTCAATCCCAATGCAGTCT 5b TAATCCCAGCTACTCCGCAGA 
5c AGAGCGTTGAATAGCCATTG   
6a TGGTACTATCACATGCATGCC 6b TGGTGGGCTGCAGTCTTACT 
7a TAAGGGAGCTGTGCCTTCA 7b TTCCAATGAACTTCCCACCT 
  7c TTAGATAGGGAAGGTGGGACA 
8a AGTGTTAGATCTCCTCCACGG 8b AGGGTCAGAGAGGTCTCCAAA 
9a ATTTAAACGCTGGGCTGCT 9b AGAAGCACACAGAAAAGGCA 
10a ATCCCAGCCTCTCACTCTCAT 10b CCACTGAGCTTTGTAAACCCA 
11a TGAACTTAAGTGATCTGCCCA 11b AGGGATGCCAGTATAAGGCTT 
 Supplementary Table 3. Characteristics of normoglycemic controls.  
 
        
  
Subjects for sequencing 
 (n=18) 
Subjects for genotyping SNPs 
(n=105) 
Men Number  10 52 
 
Age (y: mean ± SD) 64.0 ± 4.4 68.3 ± 8.1 
 
BMI (mean ± SD) 22.6 ± 2.0 22.5 ± 2.6 
 
Fasting Plasma Glucose (mmol/l: mean± SD) 4.86 ± 0.21 4.74 ± 0.31 
 
HbA1c (%: mean±SD) 5.64 ± 0.12 5.45± 0.17 
Women Number 8 53 
 
Age (y: mean ± SD) 61.1 ± 6.1 66.5 ± 8.3 
 
BMI (mean ± SD) 21.4 ± 2.3 21.7 ± 2.8 
 
Fasting Plasma Glucose (mmol/l: mean± SD) 4.66 ± 0.29 4.68 ± 0.38 




SD: Standard deviation. 
  
Supplementary Table 4. Missense SNPs of MODY genes in 10 index cases. 
   Number of Alleles  
   Index cases (n=10)  
Gene SNP Major/Minor Major Minor 
Minor Allele 
Frequency [MAF] 
      
HNF1A I27L C/A 8 12 0.386 
c
 
HNF1A S487N A/G 9 11 0.341 
c
 





       





      
a
 Additional index case #6. 
b
 Additional index case #2. 
c
 Frequency in HapMap-JPT. 
d
 Frequency in 105 normoglycemic controls. 
Supplementary Table 5. Nucleotide changes in coding exons of 7 genes in the linkage region in index cases from 4 families. 
   Number of Alleles  
   Index cases (n=4)  
Gene SNP Major/Minor Major Minor 
Minor Allele 
Frequency [MAF] 
      
NCOA1 P504P A/T 7 1 0.307 
a
 
      
FOSL2 R198H G/A 7 1 0.004 
b
 
      
KHK V49I G/A 5 3 0.166 
a
 
      
a
 Frequency in HapMap-JPT. 
b
 Frequency in 105 normoglycemic controls. 
 

